Responses
Case report
Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1
Compose a Response to This Article
Other responses
Jump to comment:
- Published on: 21 May 2021
- Published on: 21 May 2021Rate of incidence...
The data that is represented in footnote 21 (rate of 6 in 42,000 vs. the rate of .08 - 1.1 in 100,000) is significant. It represents approximately a 1 in 7,000 rate! I think that this is worth highlighting in a separate article.
Conflict of Interest:
None declared.